Compare iShares China Large-Cap ETF (FXI) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Stryker Corporation — how do they compare? iShares China Large-Cap ETF trades at $34.25 (market cap $3.86B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 27.5× iShares China Large-Cap ETF's market cap, and Stryker Corporation pays a 1.27% dividend while iShares China Large-Cap ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares China Large-Cap ETF for 150 Days and Stryker Corporation for 21 Days on average.
| FXI | SYK | |
|---|---|---|
Market Cap | $3.86B | $106.24B |
Volume | 16,323,837 | 2,982,001 |
52-Week High | $41.08 | $388.35 |
52-Week Low | $31.59 | $269.75 |
Typical Hold Time | 150 Days | 21 Days |
Sector | — | Health |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $34.25, up 2.48% today but facing significant technical headwinds with a bearish overall signal. The ETF shows compelling valuation metrics with a P/E ratio of 11.10 versus the S&P 500's 22.54, offering potential value for investors seeking China exposure. Recent developments include the Trump-Xi summit in late September 2026, which may provide incremental risk reduction in U.S.-China relations.
The outlook remains cautious due to China's economic challenges including industrial overcapacity and weak domestic consumption. While the valuation discount presents opportunity, geopolitical risks and technical weakness suggest limited near-term upside. Key catalysts include China's monetary policy stance and progress on trade relations with the U.S.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
